Malignant hyperthermia during sevoflurane administration.
Ducart
A
A
Department of Anesthesiology and Critical Care, CHU Pitié-Salpêtrière, Paris, France.
Adnet
P
P
Renaud
B
B
Riou
B
B
Krivosic-Horber
R
R
D000328:Adult; D000777:Anesthetics / Q000009:adverse effects*; D002110:Caffeine; D004198:Disease Susceptibility / Q000175:diagnosis; D004987:Ethers / Q000009:adverse effects*; D005260:Female; D006221:Halothane; D006801:Humans; D008305:Malignant Hyperthermia / Q000175:diagnosis / Q000209:etiology*; D008738:Methyl Ethers; D000077149:Sevoflurane
D000777:Anesthetics; D004987:Ethers; D008738:Methyl Ethers; D000077149:Sevoflurane; D002110:Caffeine; D006221:Halothane